It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Vancomycin-resistant Enterococcus faecium (VRE) presents significant challenges in healthcare, particularly for hospitalized and immunocompromised patients, including astronauts with dysregulated immune function. We investigated 42 clinical E. faecium isolates in simulated microgravity (sim. µg) using a 2-D Clinostat, with standard gravity conditions (1 g) as a control. Isolates were tested against 22 antibiotics and characterized for biofilm formation and desiccation tolerance. Results showed varied responses in minimum inhibitory concentration (MIC) values for seven antibiotics after sim. µg exposure. Additionally, 55% of isolates showed a trend of increased biofilm production, and 59% improved desiccation tolerance. This investigation provides initial insights into E. faecium’s changes in response to simulated spaceflight, revealing shifts in antibiotic resistance, biofilm formation, and desiccation tolerance. The observed adaptability emphasizes the need to further understand VRE’s resilience to microgravity, which is crucial for preventing infections and ensuring crew health on future long-duration space missions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 German Aerospace Center (DLR), Institute of Aerospace Medicine, Aerospace Microbiology, Cologne, Germany (GRID:grid.7551.6) (ISNI:0000 0000 8983 7915); University Hospital of Cologne, Institute for Medical Microbiology, Immunology and Hygiene, Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X)
2 German Aerospace Center (DLR), Institute of Aerospace Medicine, Aerospace Microbiology, Cologne, Germany (GRID:grid.7551.6) (ISNI:0000 0000 8983 7915)
3 University Hospital of Cologne, Institute for Medical Microbiology, Immunology and Hygiene, Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X)
4 Brigham and Women’s Hospital, Department of Cardiac Surgery, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)